2026-04-17T05:37:03Zhttps://recercat.cat/oai/requestoai:recercat.cat:11351/144222026-04-03T00:56:15Zcom_2072_378070com_2072_378040col_2072_378092
RECERCAT
author
Martínez-Castelao, Alberto
author
Gorriz, Jose Luis
author
FERNANDEZ-FERNANDEZ, BEATRIZ
author
Soler, María José
author
Navarro-González, Juan F.
2026-04-03T00:56:15Z
2026-04-03T00:56:15Z
2026-04-01T12:48:25Z2026-04-01T12:48:25Z2025-12
https://hdl.handle.net/11351/14422
Chronic kidney disease; Diabetes mellitus; Diabetic kidney diseaseMalaltia renal crònica; Diabetis mellitus; Malaltia renal diabèticaEnfermedad renal crónica; Diabetes mellitus; Enfermedad renal diabéticaDiabetes mellitus (DM) continues to be a global world health problem. Despite medical advances, both DM and chronic kidney disease (CKD) remain global health issues with high mortality and limited options to prevent end-stage renal failure. Current therapies encompass five classes of drugs: (1) angiotensin-converting-enzyme inhibitors (ACEI) or angiotensin II receptor blockers (AIIRB); (2) sodium-glucose-transporter 2 (SGLT2) inhibitors; (3) glucagon-like peptide-1 receptor agonists (GLP-1 RA); and (4) an antagonist of type 1 endothelin receptor (ET1R) with proven efficacy to reduce albuminuria and proteinuria. (5) The mineralocorticoid receptor antagonist (MRA) finerenone has been tested in RCTs as a kidney protective agent. In our review, we summarize many of the principal trials that have generated evidence in this regard. Many novel agents—many of them proven not only for DM management but also for the treatment of obesity with or without DM or heart failure (HF)—are now in development and may be added to the five classical pillars: other non-steroidal MRA (balcinrenone); aldosterone synthase inhibitors (baxdrostat and vicadrostat); other GLP-1 RA (tirzepatide, survodutide, retatrutide, and cagrilintide); ET1 R antagonists, (zibotentan); and soluble guanylate cyclase activators (avenciguat). These new agents aim to slow disease progression further and reduce cardiovascular risk. Future strategies rely on integrated, patient-centered approaches and personalized therapy to curb renal disease and its related complications.
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess
Diabetis - Tractament
Nefropaties diabètiques - Tractament
Insuficiència renal crònica - Tractament
Antidiabètics - Ús terapèutic
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Hypoglycemic Agents
Other subheadings::Other subheadings::/therapeutic use
DISEASES::Endocrine System Diseases::Diabetes Mellitus::Diabetes Complications::Diabetic Nephropathies
Other subheadings::Other subheadings::Other subheadings::/drug therapy
DISEASES::Endocrine System Diseases::Diabetes Mellitus
DISEASES::Male Urogenital Diseases::Urologic Diseases::Kidney Diseases::Renal Insufficiency::Renal Insufficiency, Chronic
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::efectos fisiológicos de los fármacos::hipoglicemiantes
Otros calificadores::Otros calificadores::/uso terapéutico
ENFERMEDADES::enfermedades del sistema endocrino::diabetes mellitus::complicaciones de la diabetes::nefropatías diabéticas
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
ENFERMEDADES::enfermedades del sistema endocrino::diabetes mellitus
ENFERMEDADES::enfermedades urogenitales masculinas::enfermedades urológicas::enfermedades renales::insuficiencia renal::insuficiencia renal crónica
Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion